Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)

Lisbon 1099-023

1 studies enrolling now · 1 studies all time

What they study most

Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

Studies at this site

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now